150 related articles for article (PubMed ID: 19914686)
1. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk.
Khasnis AA; Calabrese LH
Semin Arthritis Rheum; 2010 Oct; 40(2):147-63. PubMed ID: 19914686
[TBL] [Abstract][Full Text] [Related]
2. Tuberculosis associated with therapy against tumor necrosis factor alpha.
Winthrop KL; Siegel JN; Jereb J; Taylor Z; Iademarco MF
Arthritis Rheum; 2005 Oct; 52(10):2968-74. PubMed ID: 16200576
[No Abstract] [Full Text] [Related]
3. Was risk properly assessed in Carter, et al's safety assessment of tumor necrosis factor antagonists during pregnancy?
Winger EE; Reed JL
J Rheumatol; 2009 Sep; 36(9):2122; author reply 2123. PubMed ID: 19738224
[No Abstract] [Full Text] [Related]
4. Infection and anti-tumor necrosis factor-alpha therapy.
Zandman-Goddard G
Isr Med Assoc J; 2003 Nov; 5(11):814-6. PubMed ID: 14650109
[No Abstract] [Full Text] [Related]
5. [Rheumatology. TNF alpha-inhibitors: infection risks? Practical recommendations].
Faucherre M; Pazar B; So A; Aubry-Rozier B
Rev Med Suisse; 2011 Jan; 7(277):75-6, 78-9. PubMed ID: 21309182
[TBL] [Abstract][Full Text] [Related]
6. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
Mariette X
Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
[No Abstract] [Full Text] [Related]
7. Comment on prescribing tumor necrosis factor inhibitors.
Hanauer LB
Arthritis Rheum; 2002 Jun; 47(3):347-8. PubMed ID: 12115169
[No Abstract] [Full Text] [Related]
8. Making tumor necrosis factor blockers safer: a prescriber's consumptive challenge.
Keane J; Ní Cheallaigh C
J Rheumatol; 2008 Jul; 35(7):1238-9. PubMed ID: 18597413
[No Abstract] [Full Text] [Related]
9. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
[No Abstract] [Full Text] [Related]
10. Biologic agents in the treatment of rheumatic diseases with chronic viral infection. Where are we?
Wendling D; Di Martino V; Herbein G
J Rheumatol; 2009 Jun; 36(6):1107-8. PubMed ID: 19509089
[No Abstract] [Full Text] [Related]
11. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
[No Abstract] [Full Text] [Related]
12. Granulomatous lung disease occurring during etanercept treatment.
Phillips K; Weinblatt M
Arthritis Rheum; 2005 Aug; 53(4):618-20. PubMed ID: 16082636
[No Abstract] [Full Text] [Related]
13. Tumor necrosis factor-alpha blocker induced tuberculosis.
Kharbanda P; Dagaonkar R; Balakrishnan C; Udwadia ZF
J Rheumatol; 2010 Jul; 37(7):1542; author reply 1543. PubMed ID: 20595292
[No Abstract] [Full Text] [Related]
14. Should tuberculin skin test be positive to give latent tuberculosis treatment before tumor necrosis factor-alpha inhibitors in selected patients in developing countries?
Abud-Mendoza C; Martínez-Martínez MU; DE Jesús Macías-Mendoza J; Magaña-Aquino M
J Rheumatol; 2010 Mar; 37(3):672-3; author reply 673. PubMed ID: 20197567
[No Abstract] [Full Text] [Related]
15. Recommended screening strategy for preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India - followup report.
Malaviya AN; Kapoor S; Garg S; Rawat R
J Rheumatol; 2010 Jan; 37(1):209. PubMed ID: 20040648
[No Abstract] [Full Text] [Related]
16. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0.
Carmona L; Descalzo MA; Ruiz-Montesinos D; Manero-Ruiz FJ; Perez-Pampin E; Gomez-Reino JJ;
Rheumatology (Oxford); 2011 Jan; 50(1):85-92. PubMed ID: 20601654
[TBL] [Abstract][Full Text] [Related]
17. Neurological complications of infliximab.
Tektonidou MG
J Rheumatol; 2007 Jan; 34(1):237; author reply 237-8. PubMed ID: 17216701
[No Abstract] [Full Text] [Related]
18. Tumor necrosis factor inhibitors and risk of peripheral neuropathy in patients with rheumatic diseases.
Etminan M; Sodhi M; Samii A; Carleton BC; Kezouh A; Antonio Avina-Zubieta J
Semin Arthritis Rheum; 2019 Jun; 48(6):1083-1086. PubMed ID: 30337056
[TBL] [Abstract][Full Text] [Related]
19. Management of accelerated pulmonary nodulosis following etanercept therapy in a patient with rheumatoid arthritis.
Watson P; Simler N; Screaton N; Lillicrap M
Rheumatology (Oxford); 2008 Jun; 47(6):928-9. PubMed ID: 18385217
[No Abstract] [Full Text] [Related]
20. Do antitumor necrosis factor agents increase the risk of postoperative orthopedic infections?
Pappas DA; Giles JT
Curr Opin Rheumatol; 2008 Jul; 20(4):450-6. PubMed ID: 18525360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
